Skip to content

Clinical study of remimazolam tosilate for bronchoscopy in children

Clinical study of remimazolam tosilate for bronchoscopy in children

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065232
Enrollment
Unknown
Registered
2022-11-01
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory diseases

Interventions

1 to 3 years old:Intravenous infusion of rimazolam toluenesulfonic acid 0.2mg/kg
3 (not included) -6 years old:Intravenous infusion of rimazolam toluenesulfonic acid 0.3mg/kg
rimazolam Group:I.V. rimazolam 0.2mg/kg
propofol group:I.V. propofol 2mg/kg
midazolam group:I.V. midazolam 0.2mg/kg

Sponsors

Jinan Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1) Age 1-6, both sexes; 2) Children undergoing routine bronchoscopy; 3) American Society of Anesthesiologists ASA? or ?; 4) BMI 18-30kg/m2; 5) Informed consent, volunteer to participate in the trial, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Allergic or contraindicated to benzodiazepines, opioids, propofol, lidocaine and their drug components; 2) Anemia or thrombocytopenia, Hb < 90g/L, PLT < 80×109/L; 3) Abnormal liver function, AST and/or ALT=2.5×ULN, TBIL=1.5×ULN; 4) Abnormal renal function, serum creatinine greater than the upper limit of normal; 5) Patients with severe congenital heart disease; 6) Severe pneumonia with dyspnea and SpO2 < 90% without oxygen inhalation; 7) Suspected asthma, exogenous airway foreign body, tracheobronchial stenosis, pulmonary dysplasia, emphysema, airway space-occupying lesions and hemoptysis; 8) Patients with neuromuscular system diseases or mental diseases; 9) Suspected abuse of narcotic analgesics or sedatives; 10) Those who are predicted to have or have had difficult airway; 11) The expected time of bronchoscopy or treatment is greater than 30 minutes; 12) Subjects deemed unfit to participate in this study by the investigator.

Design outcomes

Primary

MeasureTime frame
Sedation success rate;

Secondary

MeasureTime frame
The depth of sedation;CSI index;Systolic blood pressure;Diastolic blood pressure;Heart rate;Pulse oxygen saturation;Sedation induction time;Sedation time to complete recovery;Adverse reactions;Satisfaction;

Countries

China

Contacts

Public ContactWang Shaochao

Jinan Children's Hospital

330876630@qq.com+86 13793189148

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026